Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Onco boards 2024 > Tumor Specific 25% AB > Flashcards

Tumor Specific 25% AB Flashcards

Skin/Sq, STS, FISS, GI, endocrine

1
Q

What percentage of cutaneous tumors are malignant?

A

20-40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

List the top 4 most common skin tumors in cats.

A

basal cell tumor (~25%) > MST > SCC ? fibrosarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Predisposing factors for SCC of the nasal planum, pinna, head and neck in cats?

A

white fur, UV light

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Human syndrome xeroderma pigmentosum (XP) results in UV-induced skin cancer because it is deficient in what type of DNA repair?

A

nucleotide excision repair

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How does papillomavirus result in neoplastic transformation?

A
  • interaction of papilloma viral proteins with cellular proteins
  • destabilization of p53 by viral protein E6 and inhibition of pRB by viral protein E7
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How is disruption of p53 with E6 characterized on IHC?

A

increased levels of p16 protein

E6 protein of HPV types 16 and 18 interacts with the E3 ubiquitin protein ligase, resulting in ubiquitination and proteolysis of tumor protein p53. E7 inactivates retinoblastoma protein (Rb) by phosphorylation followed by an increase of free eukaryotic transcription factor E2F (E2F) in the cell. This leads to an increase of cyclin-dependent kinase inhibitor p16, that is used as an immunohistochemical marker of HPV-associated OSCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What percentage of cutaneous SCC in cats in “UV-protected” (unexposed) areas are positive for papilloma virus via PCR DNA amplification?

A

76%

vs 42% in UV exposed areas

(no correlation in cats between virus and UV exposure; different in people)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the most common skin tumor in dogs?

A

MCT (~17%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which mutation is most common in human SCC?

A

p53

30% dogs
feline actinic keratosis 79%
feline Bowen’s in situ carcinoma 18%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which gene is affected by a loss of function mutation in GSD resulting in nodular dermatofibrosis? Which cancer is this associated with?

A
  • Birt-Hogg-Dube (BHD) have to be heterozygous or will die
  • renal cystadenocarcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which RAF sand VEGF/PDGFR TKI is associated with rapid development of actinic keratosis and invasive SCC in people?

A

sorafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which epithelial membrane glycoprotein is specific for BCC?

A

BerEP4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Incidence of BCC in dogs? At risk breeds?

A
  • 6%
  • Cocker Spaniel, Poodle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Histologic subtypes of BCC?

A

solid, keratinizing, clear cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Behavior of BCC in dogs?

A
  • low grade malignancy
  • local recurrence possible
  • no mets reported
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Incidence of BCC in cats? Breeds?

A
  • 10-26%
  • Siamese, Himalayans, DLH, Persain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

BCC behavior in cats?

A
  • ~10% may be malignant based on stroll invasion, vascular invasion, high MI, LN mets
  • pulmonary mets have been reproted
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Recommended margins for BCC removal?

A

5-10 mm surgical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Growth pattern of papillomas?

A

exophytic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Surgical excision is often curative for papillomas that do not spontaneously regress. Which drug can be used for patients with multiple lesions?

A

azithromycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Define SCC in situ.

A

carcinoma that has not penetrated the basement membrane of the epithelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Causative agent of carcinoma in situ in cats?

A

Felis catus PV type 1

  • when multiple present termed Bowen’s carcinoma or multicentric Papilloma virus induced carcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is identified on histopathology for UV induced SCC?

A

actinic keratosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

DFI and MST for cats with solitary SCC in situ of the nasal planum/pinna treated with surgery alone?

A

DFI 594d (19.8 mo)
MST 675d (22.5 mo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Alternative treatment for solitary SCC in situ in cat nose/face?

A

Strontium-90 plesiotherapy

14/14 CR, >3000d OST

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Cat breeds at decreased risk for cutaneous SCC?

A
  • Siamese, Himalayan, and Persian
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Dog breeds at risk for cutaneous SCC?

A

Labs and goldens - nasal planum SCC
blood hounds, Basset hounds, standard poodles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Paraneoplastic syndrome associated with cutaneous SCC in cats?

A

hypercalcemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Metastatic rate of cutaneous SCC in cats?

A

5.3% ; primarily LN in 66%

(VCO 2023; reported higher if nasal planum in Withrow ~40%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Metastatic rate of cutaneous SCC in dogs?

A

4.39% all LN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Response rate to electrochemotherapy for cats with cutaneous SCC?

A

82% CR for 2 mo to 3 yr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

List the tumors arising from the hair follicle (most are benign).

A

Infundibular keratinizing Acanthoma
Tricholemmoma
Trichoblastoma
Trichoepithelioma
malignant trichoepithelioma
Pilomatircoma
Malignant pilomatricoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Treatment for infundibular keratinizing acanthoma when surgery is not possible?

A

isotretinoin (1.7-3.7 mg/kg/d)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

How is malignant trichoepithelioma differentiated from benign?

A
  • invasion into surrounding tissues
  • LN involvement
  • high MI
  • highly metastatic, need wide excision
  • AKA matrical carcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

How is malignant pilomatricoma differentiated from benign?

A
  • Can be difficult but invasion primarily into bone
  • highly metastatic to lungs, LN, bone, mammary gland, and skin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Which breeds are predisposed to sebaceous gland tumors?

A

Mini schnauzers, beagles, poodles, and cocker spaniels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Which signalment characteristic is common in dogs with sebaceous gland carcinomas?

A

Intact male

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Which proteins have been shown to be expressed in canine cutaneous neuroendocrine carcinoma?

A

B-catenin and E-cadherin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

How do patients with ear canal tumors present?

A

Mass effect, chronic otitis, partial deafness, pain on opening, mouth, neuro signs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Differentials for tumors of the ear canal.

A

Ceruminous gland adenocarcinoma (most common in dogs & cats)&raquo_space; SCC, undifferentiated carcinoma, BCC, HSA, MCT, melanoma, and benign fibroma, papilloma, polyps, etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Predisposed breeds for ceruminous gland adenocarcinoma?

A

cocker spaniel, GSD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Are benign or maligner ceruminous gland adenocarcinoma more common?

A

malignant in cat (~70%), unknown in dog

  • staging always recommended
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Staging scheme for ear canal tumors?

A

T1 = confined to the external or horizontal canal

T2 = extending beyond the tympanic membrane

T3 = extending beyond the middle ear/bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Most common surgical procedure for ear canal tumors?

A

TECA-LBO

cat MST = 42 - 50.3 mo (~4 yr)

dog MST = not reached at 36 mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

PFS for dogs (5) and cats (6) with ear canal tumors treated with 12 x 4 Gy = 48 Gy?

A

39.5 mo

56% 1 year PFS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Mitosis per 10 hpf associated with more favorable outcome for cats with ear canal tumors?

A

</=2 MST 180 mo
>/= 3 MST 24 mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Dog presents with head tilt to the left, bilateral ventral strabismus, OS no menace, elevated 3rd eyelids bilaterally – where is ear tumor?

A

left middle ear

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Dog presents with falling to the left when shaking head, positional nystagmus fast phase to the left and a miotic pupil OD – where is ear tumor?

A

left brain stem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

MST for a cat with ear canal tumor presenting with neurologic signs?

A

1.5 mo

vs 15.5 mo if not neurologic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

List the 3 histologic subtypes described for cats with ear canal tumors and their associated MST.

A

1) ceruminous gland adenocarcinoma 49 mo

2) SCC 3.8 mo

3) carcinoma of unknown origin 5.7 mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

MST for a cat with an ear canal tumor presenting with extension beyond the ear canal?

A

4 mo

vs 21.7 mo if no extension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Which factor has been shown to prognostic in dogs with ear canal tumors?

A

extension beyond the ear canal (T3)

if present MST 6 mo vs 30 mo if not

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

List the most common malignant digit tumors in dogs?

A

SCC 47% > melanoma 24% > STS 13% > MCT 8% > OSA 3%

others: round cell sarcoma, adenocarcinoma, malignant adnexal tumor, HSA, LSA, chondrosarcoma, giant cell tumor of bone, synovial cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

What percentage of dogs with digital SCC have multiple digits involved?

A

3%

Predisposed breeds: standard poodle, black labs, giant schnauzers, setters, rotties

THINK BIG AND BLACK

except doxins and flat coated retrievers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Which limbs are more commonly affected by digit tumors?

A

thoracic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Predisposed breed to digital melanoma?

A

Scottish Terrier

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Rate of disagreement amongst pathologist when diagnosing digital tumors?

A

20%

75% doesn’t matter except SCC and IKA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Most common digital tumors in cats?

A

SCC 25% > fibrosarcoma 23% > adenocarcinoma 22% > OSA 8% > HSA 8% > MCT 7%

others: giant cell of bone, fibrous histiocytoma, sarcoma, melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Which tumor types have been reported to affected multiple digits in cats?

A

fibrosarcoma, adenocarcinoma, SCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Acrometastatsis AKA

A

lung digit syndrome

occurs in cats with lung tumors. Case series 88% of cats had acrometastsis and only 13% primary SCC of the digit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

MST cats with acrometastasis?

A

5 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

MST cats with digital SCC treated with surgery?

A

30 weeks
~7 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Frequency of bone lysis in dogs with digital SCC? Melanoma?

A

80% - SCC

5-100% - melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Metastatic rate canine digital SCC?

A

6%-13% at time of diagnosis

9%-17% later

Subungual may be a BETTER prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Metastatic rate canine digital melanoma?

A

32%-40% at time of diagnosis

additional 10%-26% after definitive treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Recommended treatment for most digital tumors?

A

partial foot amputation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Cytology of SCC + lysis of P3 – what is the metastatic rate?

A

20-30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

1 year and 2 year survival rate k9 SCC of the digit treated with surgery alone?

A

1 year = 50-80%

2 year = 18-62%

better if subungual

1 year = 95%

2 year = 74%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

1 and 2 year survival rate K9 digital melanoma treated with surgery alone?

A

mst 12 mths
1 year = 42% - 57%
2 year = 13-36%

  • other study added carbo with no difference in survival: 1 year 89%, 2 year 67%, MST 1350d (45 mo)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

MST, 1 year, and 2 year survival rate for dogs with melanoma treated with digit amputation and murine xenogeneic vaccine +/- chemo and RT?

A

JVIM 2011 (Manley et al)

MST 476 days (15.8 mo)

1 year 63%

2 year 32%

Metastasis poor prognosis (distant>local)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

Prognostic factors for digital melanoma?

A
  • Distant mets – poor
  • Lymphatic invasion – poor
  • MI ≥3 in 10 random hpf – poor
  • ≥20% nuclear atypia – poor
  • Presence of ulceration – poor
  • ≥15% Ki67 index – poor
  • Extension beyond the dermis – poor
  • tumor thickness >0.95 cm - poor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

MSU panel from dog with digital melanoma:
- Ki67 10%
- >30% nuclear atypia
- MC >4/10hpf
What is the prognosis and which factor is swaying that?

A

Poor - both MC and nuclear atypia

ki67 okay >/= 15% assocaited with poor prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Most common location for cutaneous SCC in dogs? Cats?

A

abdominal skin - dogs
nasal planum - cats

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

Rate of histologic changes suggestive of solar radiation in cat and dog SCC?

A

57%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Which histopathologic changes of cutaneous SCC are more likely to be associated with aggressive behavior?

A

presence of myofibroblasts, desk-plastic reaction, and incomplete margins

(suggest metastasis and poorly differentiated disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Which histologic factor has been shown the be associated with a more favorable survival in dogs with cutaneous SCC?

A

actinic change (solar) MST 1359d (45.3 mo, ~4 yr)

vs no solar changes 608d (20.2 mo, ~1.5 yr)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Which procedure can be used in cats with nasal planum SCC following curative intent surgery (nasal planectomy) to maintain aesthetics?

A

Lip to nose flap - minimal SE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

OST for cats receiving SRT for facial SCC? AE?

A

118-991 days

Acute: alopecia, epilation, erythema
Late: alopecia, pigmentation, leukotrichia

4 mths to .2.5 year?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Cats with nasal planum SCC treated with strontium 90 have a favorable prognosis with DFI reported of ~2 years. Which protocol has been shown to result in a significantly longer DFI?

A

fractionated better than single dose protocol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Response rate of nasal planum SCC to Sr90? Local recurrence rate?

A

~75%

17%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Prognostic factors associated with response to Sr90 in cats with nasal planum SCC?

A

early stage disease, absence of concurrent problem, CR - favorable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Response rate of feline SCC of the head and neck to photodynamic therapy?

A

84% RR (61% CR, 22% PR)

PFS mean 35 mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Does oclacitinib predispose to cancer?

A

no

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

Which pathway has been found to be persistently activated in cutaneous papillomas in dogs?

A

PI3k/akt/mTOR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

True or false: Felis catus papillomaryvirus type 2 virus-like particle vaccine reduces FcaPV-2 viral loads?

A

False

  • but is safe
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

What is the DFI for cats with incompletely excised sarcoids of the face?

A

250 d (~8.5 mo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

What is the recurrence rate of feline facial sarcoids following surgery?

A

40.5%

11.1% even with complete margins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Incidence of STS in dog? Cat?

A

Dog - 15% all skin/sq tumor
Cat 5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

What are predisposing factors to STS in dogs?

A
  • RT
  • Trauma
  • foreign body
  • orothopedic implatns
  • Spirocerca lupi
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

Subclassifications of STS

A

fibrosarcoma
perivascular wall tumor
peripheral nerve sheath tumor (non-brachial plexus)
liposarcoma
myxosarcoma
pleomorphic carcoma
malignant mesenchymoma
undifferentiated sarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

Biologic behavior of STS

A

locally aggressive with low to moderate risk of distant metastasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

What is nodular fascitits?

A

AKA fibrzomatosis, pseuodsarcomatous, fibromatosis

  • benign non-neoplastic lesions arising fromt he SQ fascia and superficial portions of the deep fascia in dogs
  • Histo: large plump or spindle shaped fibroblast in a stroll network of variable amounts of collagen/reticular fibers
  • can be misdiagnosed as fibrosarcomas
  • Do not met, local recurrence possible following wide resection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

STS grade I

A
  • Differentiation: resembles normal adult mesenchymal tissue
  • Mitosis: 0-9/10hpf
  • Necrosis: none

cumaltive score </=4 for 3 categories

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

What is assessed when grading STS?

A

differentiation, mitosis, necrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

STS grade II

A
  • Differentiation: specific histologic subtype
  • Mitosis: 10-19/10 hpf
  • Necrosis: <50%

cumulative score 5-6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

STS grade III

A
  • Differentiation: undifferentiated
  • Mitosis: >20/10 hpf
  • Necrosis: >50%

cumulative score >/=7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

Fibrosarcoma: cell type, histo features, IHC

A
  • fibroblast/fibrocyte
  • interwoven bundles, herring bone pattern, pronounced collagen stroma
  • no IHC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

Myxosarcoma: cell type, histo features, IHC

A
  • fibroblast/fibrocyte
  • stallate or spindle shaped cells in mucinous stroma
  • no IHC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

Pleomorphic sarcoma (malignant fibrous histiocytoma): cell type, histo features, IHC

A
  • primitive mesenchymal cells (fibroblasts or myofibroblast)
  • mix of fibroblastic cell and karyomegalic, multinucleate historic cells
  • IHC +: lysozyme 29-100%, MCH II 70%, desmin 86%, viment
  • IHC - : S-100, CD18
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
100
Q

Perivascular wall tumo: cell type, histo features, IHC

A
  • pericyte, myopericye, smooth myocyte
  • vascular growth pattern
  • IHC+: calponis, pan actin, smooth muscle actin 50%
    -IHC-: S-100, NSE, GFAP, myoglobin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
101
Q

Peripheral nerve sheath tumor: cell type, histo features, IHC

A
  • Schwann cell, neurofibroblast
  • bundles and whorls around collagen bundles, Antoni A and B
  • IHC+: NSE 45-82%, S-100 50-100%, neuofilament 82%, NGFR 47%, myoglobin 64%, GFAP 0-35%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
102
Q

Liposarcoma: cell type, histo features, IHC

A
  • lipoblast, lipocyte
  • polygonal cells with vacuolated cytoplasm
  • IHC+: MDM2 67-75%. CDK4 (variable)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
103
Q

Rhabdomyosarcoma: cell type, histo features, IHC

A
  • skeletal muscle myoblast, skeletal myocyte
  • cytoplasmic striation, racket and strap cells
  • IHC+: desmin, S-100 75%, NSE 50%, GFAP 50%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
104
Q

Lymphangiosarcoma: cell type, histo features, IHC

A
  • lymph tissue no cell type given
  • irregular vascular channels with single layer of plump spine cells and no RBCs
  • IHC+ PROX-1 80-88%, Factor VIII related Ag 100%, LYVE-1 80%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
105
Q

Mesenchymoma: cell type, histo features, IHC

A
  • multiple cell types
  • multiple soft tissue mesenchyme components
  • no IHC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

Differentials for S-100 positive STS?

A

peripheral nerve sheath tumor, rhabomysoarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
107
Q

Signalment differences for fibrosarcomas?

A
  • Younger dogs than any other subtype
  • oral location possible
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
108
Q

Behavior of fibrosarcomas?

A
  • very likely to recur after incomplete excision
  • can have high MC but be low grade (HiLo)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
109
Q

Breeds pleomorphic sarcomas or malignant fibrous histiocytoma?

A

Flat coated retrievers, Rotties, goldens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
110
Q

Characteristic IHC for malignant fibrous histiocytomas?

A

vimentin +, CD18 -

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
111
Q

Aggressive subtype malignant fibrous histiocytoma?

A

Giant cell pleomorphic tumors
- highly metastatic to SQ, LN, liver, lungs
- MST 61 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
112
Q

Most common location of myxosarcomas?

A
  • SQ of trunk and limbs but reports from heart, eye, and brain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
113
Q

Perivascular wall tumors can comprise various components of the vascular wall EXCEPT?

A

endothelial lining - this is HSA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
114
Q

How are perivascular wall tumors diagnosed/differentiated?

A

vascular growth patters (e.g. staghorn, planetoid, perivascular whirling, bundles of media)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
115
Q

Behavior of perivascular wall tumors?

A

less aggressive with low rates of local recurrence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
116
Q

Peripheral nerve sheath tumors of macroscopic nerves classification?

A
  • peripheral, root, or plexus
  • not considered part of STS of microscopic nerves
  • neuro signs
  • root or plexus worse prognosis since less ammenable to SX
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
117
Q

MST dogs with brachial plexus peripheral nerve sheet tumor treated with limb sparing compartmental resection?

A
  • MST 1303 d (43 mo, ~3.5 yr)
  • completeness of excision prognostic: incomplete 487 d (16 mo) vs 2227d (74 mo)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
118
Q

PFS and OST dogs with brachial plexus tumors treated with SRT?

A
  • PFS 240d (8 mo)
  • OST 371d (12 mo)
  • local progression reported 90% eventually
  • dogs die of local disease before mets
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
119
Q

Morphologic subtypes of lipomas?

A
  • regular
  • infiltrative
  • intermuscular
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
120
Q

Histo differentiation of lipoma vs liposarcoma?

A

lipoma- indistinct nuclei and cytoplasm resembling normal fat

liposarcoma- increased cellularity, distinct nuclei, abundant cytoplasm with one or more droplets of fat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
121
Q

Most common location for inter muscular lipomas?

A

caudal thigh of dogs between semitendinosus and semembranosus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
122
Q

Biologic behavior of inter muscular lipomas?

A

slow growing, firm, fixed, local recurrence rare after resection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
123
Q

Composition of infiltrative lipomas?

A
  • well differentiated adipose cells without evidence of anaplasia
  • cannot be differentiated by cytology or histo from lipomas
  • distinguished only by invasiveness to other tissues - CLINICAL DIAGNOSIS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
124
Q

Signalment predisposition infiltrative lipomas?

A

4:1 female to male ratio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
125
Q

Treatment infiltrative lipomas?

A

Aggressive surge usually with amputation +/- RT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
126
Q

Biologic behavior of liposarcomas

A
  • locally aggressive with low metastatic rates
  • reports to lungs, liver, spleen, and bone
  • bone, spleen, and abdominal cavity can also be PRIMARY
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
127
Q

How are liposarcomas differentiated from lipomas?

A
  • morphologic appearance
  • cyto: OIL RED O to stain lipid
  • CT: mixed-attenuating, heterogenous, multi nodular, contrast enhancing masses on PREcontrast CT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
128
Q

Prognosis liposarcoma with surgery?

A
  • wide resection: 1188d (40 mo)
  • sig different from marginal 649d (21 mo) or incisional BX (183d)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
129
Q

Histologic subtypes of liposarcomas in people?

A
  • well differentiated, myxoid, round cell, pleomorphic, dedifferentiated
  • pleomorphic highly metastatic

*not prognostic in dogs but one study showed metastasis more common with pleomorphic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
130
Q

Revised classification scheme for liposarcomas?

A
  • based on IHC expression MDM2 and CDK4
  • Ki67 higher in dedifferentiated than well differentiated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
131
Q

locations of rhabdomyosarcomas?

A

urinary bladder, retrobulbar musculature, larynx, tongue, myocardium

  • locally invasive with low to moderate metastasis to lungs, liver, spleen, kidneys, and adrenals
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
132
Q

How are rhabdomyosarcomas classified?

A

Histologically: embryonic, botryoid, alveolar, and pleomorphic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
133
Q

Rhambomyosarcoma IHC markers?

A

vimentin, skeletal muscle actin, myoglobin, myogenic, myogenic differfentiation

desmin s-100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
134
Q

Common location of embryonic rhabdo?

A

head and neck

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
135
Q

Common location of botryoid rhabdo?

A
  • urinary bladder of young, female, large breed dogs with St. Bernards over represented
  • grape like appearance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
136
Q

Rhabdo metastatic rate based on subtype?

A
  • botyroid 27%
  • embryonal and alveolar 50%
  • mets more common in dogs < 2 years of age
  • in one study all dogs under 4 died of mets or local disease MST 2.5 mo
  • no dogs over 4 died d/t tumor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
137
Q

Clinical signs of lymphangiosarcoma?

A

Usually soft, cystic like, and edematous.

Extensive edema and drainage of lymph through the skin or mass, non healing, discharging wounds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
138
Q

How can you differentiated lyphangiosarcoma from HSA with IHC?

A
  • both CD31 and factor VIII ag +
  • lymph LYVE-1 and PROX-1 positive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
139
Q

Prognosis lymphangiosarcomas?

A
  • 3 dogs no treatment MST 168 (range 60-876; 2 - 30 mo)
  • 5 dogs with alone MST 487d (range 240-941d; 8-31 mo)
  • 2 SX, RT, and chemo MST 574d
  • all dogs eventually died d/t tumor (recurrent or PD locally)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
140
Q

Splenic mesenchymoma reported - MST

A
  • better than other types of splenic sarcomas
  • MST 12 mo with 50% 1 year survival
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
141
Q

Cytologic accuracy of correctly diagnosing STS?

A

63-97%

  • always submit! disproportionate number of FALSE-NEGATIVE cytologic results associated with in-house assessment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
142
Q

Biopsy methods for STS?

A
  • Can do core, punch, incisional or excisional BUT 41% not excision will differ in grade from definitive sample
  • histologic grade UNDERESTIMATED in 29%
  • OVERESTIMATED in 12%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
143
Q

Why is excisional biopsy not preferred for STS?

A
  • may not be curative increasing morbidity and cost
  • multiple attempts at resection before definitive therapy have negative effect on survival time

REFER

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
144
Q

When should LN assessment be performed when staging STS?

A
  • if enlarged, known to be grade III, or suspect nonconlvential type
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
145
Q

Minimum recommended surgical margins STS?

A

2-3 cm lateral and 1 fascial plane deep

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
146
Q

Alternative margin system for STS?

A
  • proportional similar to MCT
  • larger tumors significantly more likely to recur
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
147
Q

Likelihood of STS recurrence with incomplete margins compared to wide resection?

A

10.5x higher

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
148
Q

When might marginal excision be okay for STS?

A
  • well circumscribed, non-infiltrative, <5 cm in diameter, located on limbs below the elbow/stifly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
149
Q

STS recurrence rates following incomplete excision based on grade?

A

I: 7% - 11%
II: 34%
III: 75% (3 of 4 dogs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
150
Q

Peripheral nerve sheath tumor recurrence rates?

A

18-20%

  • even with 60% being incompletely excised
  • size associated with recurrence, 7x more likely if >5 cm diameter
  • increasing risk 1.3x for every 1 cm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
151
Q

Recurrence risk STS based on grade?

A

5.8 fold if grade III compared to grade I & II

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
152
Q

When might active surveillance be an appropriate treatment for incompletely excised STS?

A

grade I +/- II, well circumscribed, <5cm, distal limbs

further treatment may be unnecessary in up to 93% of dogs with incomplete excised grade I tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
153
Q

STS surgical scar revised with 0.5 o 3.5 cm lateral margins - frequency of residual disease identified?

A

22%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
154
Q

Local recurrence rate for intralesional bleomycin electrochemotherapy for incompletely excised STS?

A
  • 36%
  • mean time 730d (~24 mo)
  • wound dehiscence in 14%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
155
Q

Local recurrence rate, DFI, 1- 2- 3- year disease free rate STS treated with surgery alone?

A

RR: wide 0-5%, marginal 11-29%
DFI: 368d to not reached
1 yr: 89-93%
2 yr: 78-82%
3 yr: 66-76%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
156
Q

Local recurrence rate, DFI, 1- 2- 3- year disease free rate STS treated with surgery and fractionated RT?

A

RR: 17-39%
DFI: 421d to not reached
1 yr: 71-84%
2 yr: 60-81%
3 yr: 57-81%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
157
Q

Local recurrence rate, DFI, 1- 2- 3- year disease free rate STS treated with surgery and hypo fractionated RT?

A

RR: 18-21%
DFI: 698d to not reached
1 yr: 81%
2 yr: 73%
3 yr: 73%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
158
Q

Local recurrence rate, DFI, 1- 2- 3- year disease free rate STS treated with marginal excision and electrochemotherapy?

A

RR: 17-31% (higher for grade III)
DFI: 264d to not reached
1 yr: 81-100%
2 yr:69-89%
3 yr: 69-84%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
159
Q

What is the earliest RT should be considered follow STS resection?

A

7 days to limit AE

  • other weird study found that waiting at least 4 weeks to start hypo fractionated RT improved survival
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
160
Q

Recommended RT for STS?

A
  • full course, fractionated schedule
  • optimal not defined but should be >50 Gy total
  • better local control associated with higher cumulative doses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
161
Q

MST for incompletely excised STS (non oral) treated with fractionated RT?

A

MST 2270 d (75 mo)

1 yr 80-87%
2 yr 72-87%
3 yr 92%
5 yr 76%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
162
Q

What histologic findings in STS has been associated with recurrence when treated with RT?

A

MC > 9/10 hpf

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
163
Q

Recurrence rate of STS to hypo fractionated RT (24-36 Gy) following incomplete or close resection?

A

18-21% - majority small ~ 3-4 cm, and low grade I -II (83%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
164
Q

What should you consider when treating STS with hypo fractionated protocols?

A

patient age/expected survival time - risk of late toxicity increases if living long

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
165
Q

PSF and likelihood to be tumor free following hypoRT for incompletely resected STS?

A

PFS: 698d (23 mo) - not reached

1 yr - 81%
2 yr -73%
3 yr - 73%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
166
Q

Prognosis for STS incompletely excised treated with hypofractionated RT to scar based on grade?

A

I:
- PFS 1904 d (63 mo)
- OST not reached

II:
- PFS 582d (~20 mo)
- OST not reached

III:
- PFS 292d (~10 mo)
- OST 940d (31 mo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
167
Q

RT for gross STS tumor control rates?

A
  • dose >50 Gy
  • 1 yr 50%
  • 2 yr 33%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
168
Q

Hypofractionated RT for gross STS

A
  • 20-36 Gy
  • ORR 46-50% (many SD)
  • PFI 155-419 d (5-14 mo)
  • prognostic factors: tumor location (better for limb 466d vs 110d) and previous surgery (more than 1 did worse 105d vs 420d)
  • MST 206-513 d (~7-17 mo)
  • MC used in this study did not improve PFI but did MST (757d vs 518d)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
169
Q

When can RT be considered preop for STS?

A

1) radiation field is smaller because, after surgery, the entire surgical site must be included in the field plus normal tissue margin

2) a larger number of peripheral tumor cells are inactivated with reduced contamination at surgery site

3) tumor volume reduction may make surgical resection less difficult

  • lower doses recommended <50 Gy, wound healing may be harder (is in human med)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
170
Q

Metastatic rates for STS based on grade?

A

I: 0-13%
II: 7-27%
III 22-44%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
171
Q

Median time for metastasis STS?

A

365 d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
172
Q

MTD chemo protocols for STS?

A
  • DOX
  • DOX alternating ifosfamide
  • neither shown to improve survival in dogs with grade III STS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
173
Q

How does MC work for STS? Dose?

A
  • inhibiting tumor angiogenesis and suppressing regulatory T cells
  • shown at 15 mg/m2/d but NOT 12.5 mg/m2/d

cyclophosphamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
174
Q

Wound complication rate following intralesional chemotherapy for STS?

A

47-84%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
175
Q

Poor prognostic factors for local tumor control for STS?

A

large tumor >5 cm, infiltrative tumors. tumor in locations other than distal limbs, high grade, incomplete margins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
176
Q

What is the median post STS recurrence for dogs who are euthanized due to their tumors?

A
  • 256 days (8.5 mo) vs 945 days (31 mo) median post recurrence for those who died of other caused
  • importance of wide resection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
177
Q

Proliferative markers associated with STS survival?

A

AgNOR - increased 77 times more likely to die as a result of disease

ki 67- increased 12 times more likely to die from disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
178
Q

You perform an FNA of a mass that is consistent with STS what are the next steps?

A

biopsy, chest rads, +/- referral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
179
Q

Incompletely excised STS grade II and owner cannot afford definitive RT. What is the recurrence rate? Alternative treatment options?

A
  • recurrence <10%
  • MC, hypo fractionated RT, electrochemotherapy, monitor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
180
Q

What is the survival time STS with >20MI, 10-19MI, <10MI in STS?

A

> 20 MST 236days (8 mo)
10-19 MST532 (18 mo)
<10 MST 1444 (48 mo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
181
Q

Incompletely excised gr2 STS tx with hypoRT - what is 3 yr DFI?

A

70%

182
Q

Recurrence with close margins (<3 mm) for STS based on grade?

A

I: 7-20%
II: 35%
III: 75%

183
Q

Incompletely excised STS DFI to cytoxan 10 mg/m2 EOD and piroxicam 0.3 mg/m2 daily?

A
  • 410+ days or ~14 mo (most still alive)
  • untreated 210d was significant
184
Q

With MC using cytoxan 15 mg/m2 daily + piroxicam what as found to be decreased in samples, time period?

A

28 days - microvessel density and Tregs

185
Q

Frequency of sterile hemorrhagic cystitis for MC in dogs with SRS?

A

10%

186
Q

RR of STS to chlorambucil 4 mg/m2 daily?

A
  • 20% CR and 80% SD
  • PFI 1-20 weeks
187
Q

Treatment outcomes with 5 x 6 Gy RT with MC (thalidomide 1-2 mg/kg/d + piroxicam 0.3 mg/kg/d + cytoxan 7 mg/m2 EOD)?

A
  • MC group sig longer OST 757 d (25 mo) vs 286d (9.5 mo) RT alone
  • all PFI 419 d (14 mo), MC vs RT alone did not influence
  • all OST 513 (17 mo)
  • increased tumor burden decreased survival and location other than limbs
188
Q

What is concordance between excision and pre-treatment biopsy of STS?

A

59%

189
Q

Outcome fractionated RT for incompletely excised high grade STS +/- chemotherapy?

A
  • OST 891d (29.7 mo)
  • 1 yr 85%
  • 2 yr 43%
  • 5 yr 18%
  • TTP 1581day, 52 mo (mean)
  • 24% developed mets to nodes or lungs
  • 20% local recurrence
  • increased risk of death associated with not adhering to RT schedule and prolonging RT

JVIM Cronshaw 2020

190
Q

Sensitivity and specificity of optical coherence tomography for STS margin assessment?

A

In vivo = SN 88%, SP 93%
Ex vivo = SN 83%, SP 93%

191
Q

What is in-transit metastasis?

A
  • type of metastasis in which skin cancer spreads through lymph vessel and begins to grow more than 2 cm away from primary tumor before it reaches LN
  • Reported in metastatic STS in 6 yr Staffy
192
Q

What cytologic parameter may correlate with increasing grade for STS?

A

MC >/=3

193
Q

What percentage of rhabdomyosarcomas can be diagnosed on histology with IHC withOUT use of electronmicroscopy? IHC markers?

A
  • 81% do no require EM
  • myogenin and MyoD1
194
Q

MST rhabdomyosarcoma?

A

47d - 1480d (~1.5-50 mo)

Vet path 2021

195
Q

Are platinum containing biodegradable impregmentated beads a reasonable TX for canine STS?

A
  • AE 37% (seroma, crusting, discharge, erythema)
  • concern for manufacturing inconsistencies
196
Q

STS gross response rate to SBRT (3 x 9-16Gy) or (2 x 16Gy)?

A
  • ORR 46% (36% PR, 11% CR)
  • PFS 521d (17 mo)
  • TTP 705d (~24 mo)
  • OST 713d (~23 mo)
  • disease specific OST 1,149d (38 mo)
  • location other than limbs poor prognostic indicator
  • low grade = favorable
197
Q

How prevalent are pulmonary nodules suggestive of metastasis at the time of STS diagnosis?

A
  • 11.7%
  • more likely if grade III 38%
  • 6% in both grade II and I
  • more likely if tumor present >3 mo
198
Q

DFI and OST for 20 Gy SRT to microscopic STS scar with liquid fiducial markers?

A
  • not reached >1,500 days at time of writing
  • 80% acute skin AE, 36% late
199
Q

Rhabdomyosarcomas occur in young dogs and may be confused with round cell tumors in 32% of cases. Which cytoskeleton linker protein can be used to differentiate?

A

Ezrin (membranous and cytoplasmic staining)

200
Q

In the case of SQ STS can the skin be left intact rather than resected during surgery?

A

No - 51.7% infiltrated with tumor cells

  • 100% grade III, 36% grade I
201
Q

Is there a difference in RR and DFI between intraoperative ECT with bled and adjuvant for STS?

A

No, similar

Intra op- RR 23%, DFI 81.5d
Adjuvant - RR 25%, DFI 243d

202
Q

What is the overall relative risk of tumor recurrence with complete margins vs incomplete margins for STS?

A

0.396

  • 9.8% of complete excised recur
  • 33.3% of incompletely excised recurred in this population
  • microscopically complete margins confer sig. reduced risk
203
Q

Immunotherapy for STS?

A

IL-2/agonist anti-CD40 Ab - induces long term curative responses in mice

  • 3+3 phase 1 dose finding in dogs induced tumor regression with minimal SE at 3 dosing levels
204
Q

What physical factors of perivascular wall tumors are associated with increased recurrence? Histo?

A
  • ulcerated appearance and distal extremity tumors
  • Grade, necrosis, MC, margins
  • Grade II, >50% necrosis, and high MC decreased survival
205
Q

OST for fractionated RT for infiltrative lipomas in gross and microscopic setting?

A
  • 4.8 years with no dogs thought to die from tumor
  • no difference between disease setting
206
Q

What percentage of gastric tumors are sarcomas?

A

10-13% GIST>leiomyosarcoma

207
Q

What is the metastatic rate of GIST? leiomyosarcoma?

A

32.1%, 15.3%

208
Q

Which histologic factors are associated with improved survival for GIST?

A

MC <9
strong c-Kit staining

209
Q

What is the most common visceral sarcoma?

A

leimyosarcoma 38.1%
- spleen & SI
- low local recurrence 4/7%
- Mets 40.4%

210
Q

Which vaccines have been associated with FISS?

A

inactivated rabies and FeLV most common

211
Q

Frequency of FISS?

A

1/10,000 vaccinated to 1/1,000 vacinated

212
Q

Other injections associated with FISS?

A

steroids, NSAIDs, ABX, lufenuron, microchip, suture material

213
Q

Time to tumor development FISS follow vax?

A

4 weeks to 10 years

214
Q

Are non-adjuvant vaccines safer?

A

unclear - 3 epidemiological studies did not provide evidence

215
Q

How are ISS hypothesized to develop?

A

inflammatory reaction induced by injectable leads to uncontrolled fibroblast and myofibroblast proliferation

  • supported by histo: central areas of necrosis, inflammatory cells (lymphs, Macs), multinucleate giant cells
216
Q

Immunoreactivity of ISS?

A

PDGF
EGF
TGF-b

  • non ISS are not usually positive for these growth factors
  • lymphocytes in ISS + for PDGF and may secrete to recruit Macs and lead to fibroblast proliferation
217
Q

How does ISS differ from non ISS sarcomas on histo?

A
  • FISS show increased inflammatory cells with transition area, MC, and cellular pleomorphism
  • can sometimes see AlOH adjuvant with electron probe X-ray microanalysis
  • 59% grade III
218
Q

Which photo-oncogene has been found associated with FISS?

A

c-jun

*not on other sarcomas

219
Q

Does FeLV/FIV status predispose to FISS?

A

no

220
Q

What are the exceptions in cats in regards to similar biologic behavior between STS?

A
  • ISS - large, rapid growth, arise from SQ
  • virally induced multi centric fibrosarcoma
  • rarity of peripheral nerve sheath tumors and hemangio
  • “normal sarcomas” - small, slow growing, arise from skin
221
Q

What subtypes of ISS have been described?

A

fibrosarcomas, rhabdo, undifferentiated sarcomas, extraskeletal OSAs and chonrosarcomas

222
Q

How should ISS be staged?

A

CT and/or MRI local lesion, lungs

223
Q

What CT finding has been associated with a worse prognosis for ISS?

A

presence of skip metastasis

224
Q

What % of ISS peritumoral lesions identified on CT end up being non-neoplastic on histo?

A

59%

225
Q

Minimal and preferred surgical margins for ISS?

A

Min - 2 cm lateral and deep
preferred- 5 cm lateral and 2 fascial planes deep (can go down to 3 and 1 if CT directed)

226
Q

What % of ISS are completely excised based on surgical margins?

A
  • 50% when 2 or 3 cm lateral margin
    95-97% when 4 or 5 cm lateral margins used
227
Q

What is contraindicated when ISS is suspected?

A

marginal resection or excisional biopsy

  • marginal resection, more than 1 attempt, and non boarded surgeons associated with sig decreased DFI and MST
228
Q

Median time to recurrence after marginal vs wide resection ISS?

A

marginal 79d vs 325-419d (1+ year)

  • 66d non surgeon vs 274d with surgeon
229
Q

DFI at 1 and 2 yr for ISS treated with 2, 3 cm resection vs 4, 5 cm?

A

2/3: 1 yr 35%, 2 yr 9%

4/5: 14% recurrence rate at 3 years

230
Q

Median follow up time ISS treated with compartmental resection and epirubicin?

A

1072d (35 mo)

14% recurrence

231
Q

Complication rate iSS treated with aggressive compartmental resections?

A

11-17%

  • wound dehiscence more common after wide resection of inter scapular ISS over other locations
  • overweight cats, larger tumors, ISS that require longer sx times, and defects closed in X-shape also associated with dehiscence
232
Q

Does DOX improve ISS ST?

A

no difference in one study with 49 cats treated with DOX and sx compared to sx alone

233
Q

Local recurrence rate and DFI preoperative RT and SX?

A

RR: 40-45% (398-584d post op)
DFI: 700-986d (23-32 mo) complete excision vs 112-292d (3.7-9.7 mo) incomplete

Local recurrence still reported in 42% with complete excision and 32% without

234
Q

Local recurrence in ISS treated with SX then post op RT?

A

RR: 41% mean 405d

  • one study showed that post op better than pre op RT but they treated larger tumors pre op so selection bias
235
Q

When should RT start post sx for ISS?

A

10-14 days, longer interval associated with decreased DFI and ST

236
Q

Compare definitive inent RT to hypofractionnated RT ISS

A

-dRT: PFI 37 mo
1 yr PF 63%
2 yr 60%

-hypoRT: PFI 10 mo
mST 24 mo

237
Q

Summary RT MST and 1, 2, 3 yr survival rates following surgery?

A

MST 600-1307d
1 yr 86%
2 yr 44%
3 yr 28%

238
Q

pRT for gross ISS?

A
  • not really effective
  • 7 PR and 2 CR reported after liposomal dox and 5 x 4Gy –> PFI 117d (4 mo) so not durable
  • similar for 4 x 8 Gy with no DOX PFI 4 mo, MST 7 mo
239
Q

SRT for gross ISS?

A
  • most 3 x 20 Gy
  • 3 CR, 5 PR = ORR 72%
  • PFI 242 d (8 mo)
240
Q

Metastatic rate of ISS?

A

0-26%

time to mets 265-309d (8 - 10 mo)

241
Q

ISS cell lines show sensitivity to which drugs?

A

DOX, mito, vino, CCNU, paclitaxel

242
Q

Gross ISS responses to chemotherapy?

A

ifosofamide 3% CR, 37% PR

doxo + cytoxan 50% PR

CCNU 3% CR, 21% PR

median 2.5-4 mo

carbo and Palladia ineffective in treating gross tumors

243
Q

What is a prognostic factor for using chemo to treat ISS?

A

responders 242d vs non responders 83d

244
Q

Alternative treatments for ISS?

A

IL-2: combined with surgery and iridium based brachytherapy 1 yr control rate 61%.
- When compared to sx/brachy alone IL2 increased time to relapse

Electrochemotherapy: cisplatin in tumor bed, bleo IV - improved survival compared to historic controls. mST 985d (32 mo)

245
Q

RR FISS doxo and cytoxan?

A

50% for ~125 d (4 mo)

246
Q

RR FISS to liposomal dox?

A

39% for 84 d

  • no difference between liposomal or typical DOX*
247
Q

CCNU dose cats FISS? RR?

A

38-60 mg/m2 q3 weeks

25%, 60-80d

cumulative neutropenia and lots of treatment delays

248
Q

Prognosis for cats with FISS?

A

generally considered good

  • wide resection 25-30 mo (2-3 yr)
  • marginal ~1 yr
249
Q

Which hematologic factors have been associated with decreased survival in cats with ISS?

A
  • PCV <25%
  • neutrophil:lymph, total WBC, and neutrophil count for recurrence (WBC >NLR and NC)
250
Q

Efforts to prevent FISS?

A

low limb/tail vaccination, nonadjuvanted vaccines, avoid Al based adjuvants, increase vax intervals

251
Q

3-2-1 rule

A
  • mass evident for 3 or more months
  • larger than 2 cm
  • increasing in size for 1 mo
252
Q

IHC of FISS?

A

Positive:
- vimentin 100%
- S-100 95%
- C kit 19%
- COX 2 62%
- FeLV particles 43%

Negative:
- desmin 81%

253
Q

What is the disease specific survival and local recurrence rate for cats with ISS treated with surgery and brachytherapy (post op iridium 192 interstitial implants)?

A

ST 1242d = 42 mo

54.5% local failure

multiple surgeries prior ass. with poor prongisis

254
Q

Cat presents for microscopic ISS following first surgery. Should you recommend fractionated or hypofractionated RT?

A
  • fractionated
  • 2018 paper compared the two and found for first occurrence cases benefit of fractionated RT (PFI 1430d 47 mo vs 540d 18mo pRT)
  • significance was lost when comparing recurrent ISS so can consider pRT as an alternative in these cases
255
Q

Which hormone receptor expression may be associated with worse prognosis for FISS?

A

estrogen - 64% of cases and higher MC

256
Q

What are the mechanisms of AlOH vaccines inducing FISS?

A
  • inflammation
  • double strand DNA breaks w/o inflammation
257
Q

Local recurrence rate of non-FISS sarcomas to RT?

A

37.5% hypofractionated protocol
50% fractionated

PFS hypo 164 d (5.4 mo)
PFS fractionated 2,748d (91 mo)

  • not sig likely because under powered (18 cats)
258
Q

Which drug has been shown to inhibit proteasome leading to cell death via apoptosis in vitro for FISS?

A

bortezomib

259
Q

leiomyosarcoma markers?

A

Postive:
- SMA
- Desmin +/-

Negative:
- KIT
-CD117
- S-100
- Dog1

Desmin confirms myogenic origin but does not differentiate between smooth, striated, or cardiac muscle

260
Q

What test is used to differentiate FISS from feline sarcoma virus?

A

FeLV DNA provirus+oncogene, Rapidly growing rare sarcoma in young cats, FeLV+ unlike FISS

261
Q

What growth factor does FISS express and what drug may have activity against it in vitro?

A

PDGFRβ, Masitinib

262
Q

What are some molecular mutations in FISS?

A

cJUN, p53, TGFB, PDGF, KIT

263
Q

What has resulted from changing the vaccination locations recommended for cats?

A

Increase in right limb and right flank tumors

rabies = rHL

264
Q

Sex predisposition oral tumors dog?

A

Male - OMM, tonsil SCC, odontogenic fibromas

Female - axial OSA

265
Q

Dog breed oral tumor predispostions?

A

cocker, GSD, Gordon setter, German pointers, Weimaraner, Goldens, Poodle, chow chow, boxer

*OMM more common in smaller dogs

266
Q

Most common oral tumor dog? Cat?

A

OMM > SCC > fibrosarcoma

SCC

267
Q

% of amelanotic OMM?

A

38%

268
Q

OMM IHC cocktail with 100% specificity and 94% sensitivity?

A

PNL-2, Melan A, TRP-1. TRP-2

269
Q

Rate of OMM metastasis?

A

80%

270
Q

Histologic subtypes of SCC?

A

conventional, papillary, busload, ademosquamous, spindle cell

271
Q

Pappillary SCC behavior

A
  • young dogs <9 mo
  • rostral oral cavity
272
Q

Metastatic rate non-tonsil SCC dog?

A

5-29%

site dependent rostral low caudal/tongue higher

273
Q

Metastatic rate of tonsil SCC dog?

A

73%

274
Q

% of oral tumors with bone involvement based on type?

A

OMM 57%
SCC 77%
FSA 60-72%
acan ameloblastoma 80-100%

common for SCC and FSA in cats

275
Q

OMM SX response, recurrence rate, MST, 1 yr survival?

A
  • fair to good
  • 0-59%
  • 5-17 mo
  • 21-35%
276
Q

OMM RT response, recurrence rate, MST, 1 yr survival?

A
  • good, 83-94%
  • 11-27%
  • 4-12 mo
277
Q

Overall prognosis OMM, MST, cause of death?

A
  • guarded
  • <36 mo
  • distant metastasis (if tumor removed obvi)
278
Q

SCC (dog) SX response, recurrence rate, MST, 1 yr survival?

A
  • good
  • 0-50%
  • 9-26 mo
  • 57-91%
279
Q

SCC (dog) RT response, recurrence rate, MST, 1 yr survival?

A
  • good
  • 31-42%
  • 16-36 mo
  • 72%
280
Q

Overall prognosis SCC (dog), MST, cause of death?

A
  • good to excellent
  • 26-36 mo
  • local or distant disease
281
Q

FSA (dog) SX response, recurrence rate, MST, 1 yr survival?

A
  • fair to good
  • 31-60%
  • 10-12 mo
  • 21-50%
282
Q

FSA (dog) RT response, recurrence rate, MST, 1 yr survival?

A
  • poor to fair
  • 32%
  • 7-26 mo
  • 76%
283
Q

Overall prognosis FSA (dog), MST, cause of death?

A
  • gaurded
  • 18-26 mo
  • local disease
284
Q

Acanthomatous ameloblastoma SX response, recurrence rate, MST, 1 yr survival?

A
  • excellent
  • 0-11%
  • > 28-64%
  • 72- 100%
285
Q

Acanthomatous ameloblastoma RT response, recurrence rate, MST, 1 yr survival?

A
  • excellent
  • 9-18%
  • 37 mo
  • > 85%

death rarely tumor related

286
Q

SCC (Cat) SX response, MST, 1 yr survival?

A
  • poor
  • 45 days
  • <10%
287
Q

SCC (cat) RT response and MST?

A
  • poor
  • 90d
288
Q

Overall prognosis SCC (cat), MST, cause of death?

A
  • poor to fair
  • 14 mo
  • local disease
289
Q

predisposing facts to SCC cats?

A
  • flea collars - 4 fold increase
  • canned food esp. tuna
  • smoke - 2 fold, associated with sig increase in p53 expression
  • urban environment
  • outdoor access
  • Above have been ID with no overlap in studies
  • new VCO 2023 found clay litter and flea collars to be significant
290
Q

Clinical staging oral tumors

A
291
Q

A 8 yr MN Golden presents for a tumor of his hard palate. Histopathology (large incisional) is consistent with a fibroma. How should you treat?

A

aggressively likely histologically low grade but biologically high grade FSA

292
Q

Accuracy of FNA for dx oral tumors?

A

92% dogs
96% cats

293
Q

In which oral tumor types is size associated with prognosis?

A

MM, SCC, tongue tumors

294
Q

What percentage of head rads will miss bony lysis?

A

~60%

30% noted on rads 90% on CT

295
Q

% of dogs with OMM with large LN that were not mets?

A

49%

296
Q

% of dogs with OMM with normal LN that were mets?

A

40%

297
Q

Accuracy of FNA for the detection of mets to LN in oral tumors?

A

77%

298
Q

Favorable prognostic factors for oral tumors?

A

complete resection, small diameter, rostral locations

299
Q

MST SCC cats treated with mandibulectomy and RT?

A
  • 14 mo, 1 yr survival 57%
  • non tonsil/tongues location more favorable
  • Highly location specific - other study shows MST 921 (30 mo) if rostral mandibulectomy vs 192 d if >50% of manbdible removed
300
Q

RR accelerated RT (14 fx 3.5 Gy twice daily 9 days) + carbo radio sens - cats SCC oral?

A

85% MST 163d, 5.4 mo

*similar with gemcitabine 75% MST 112d

301
Q

Which combination of treatment for oral SCC cats has resulted in CR of 73%

A

mitoxantrone and RT

MST 184d

302
Q

RR to hypofractionated RT cat SCC?

A

81% MST 174d

303
Q

RR palliative SRT cat SCC?

A
  • 39%
  • PFI 87d
  • MST 106d
  • high complication rate: mandibular fx, fibrosis, fistula
  • Higher microvessel density or more keratinzed SCC had sig shorter ST or PFI than patients w lower MVD or less keratinized SCC
304
Q

What is bmi-1? Tumor type association?

A
  • oncogene responsible for suppression of cell cycle inhibitors
  • confers resistance to chemo and RT
  • high expression associated with outcome in cats with oral SCC doing worse
305
Q

Which systemic therapies have been shown to improve outcomes in cats with gross oral SCC?

A
  • Palladia + NSAID
  • 57% RR
  • 4% CR, 9% PR, 43% SD
  • MST 123 sig. longer than cats with no Palladia 45 d
  • NSAID alone also improves survival 169d vs no NSAID 55d
306
Q

Which drug has been shown to reduce feline SCC cells in vitro and provide palliation in vivo pilot study?

A

Pamidronate

  • zoledronate has also been described with 8 Gyx4 with 44% RR and minimal AE (only decreased serum c-telopeptide which measures bone turnover)
307
Q

Prognosis for axial OSA of the head?

A

better than appendicular
- 4% met at dx
- 32-46% following definitve tx
- MST 14-18 mo

308
Q

Urban living is associated with which cancer?

A

tonsillar SCC, LSA, nasal adenocarcinoma

309
Q

Metastatic rate of tonsilar SCC at dx?

A

20% - even when confined to the tonsil micrometastasis likely in 90% of cases

310
Q

Does cervical lymphadenectomy improve outcome for tonsilar SCC?

A

No but tx with RT achieves local control for 75% cases though 1 yr survival still 10%

311
Q

What is the most common equine gastric tumor?

A

SCC

312
Q

What is the MST with tongue melanoma?

A

551d (18 mo)

313
Q

What is the survival with tongue SCC with grade?

A

Grade1 MST 16months, grd2 4months, grd3 3months; Feline 1yr survival <25%

314
Q

What is prognostic for tongue tumors?

A

size, grade, type

  • <2-4 cm improved survival
315
Q

What is undifferentiated malignancy of young dogs?

A
  • disease of young, large breed dogs
  • rapid growing cancer of palate, molars, maxilla, orbit
  • highly metastatic
  • no TX
  • 30d ST
316
Q

Where does MLO arise from?

A

mandible, maxilla, hard palate, orbit, calvarium

317
Q

Histo of MLO?

A

multiple lobules with central cartilaginous or bone matrix surrounded by a thin layer of spindle cells

318
Q

MLO imaging appearance?

A

Popcorn

319
Q

MLO rate of recurrence after sx?

A

47-58% - depends on margins and grade

  • DFI complete = 1,332d (44mo)
    incomplete = 330d (11 mo)
  • recurrence:
    grade III 78%
    II 47%
    I 30%
320
Q

MLO metastatic rate?

A

-up to 58% late in the course of disease to lungs
- time to mets 465-542 d (15-18 mo)
- worsens if incompletely excised 75% vs 25% if complete

321
Q

Which of the following has been associated with development of gastric SCC in scottish cows with papiloma virus?

A

Bracken fern ingestion
- 30% cattle that had SCC of upper GIT had concurrent bladder tumors

322
Q

Prognosis for dogs <2 year of age with oral SCC?

A

great - surgery curative (wide)

323
Q

Paraneoplastic syndrome associated with disseminated tonsillar SCC reported in dog?

A

hypoglycemia secondary to insulin like GF1 production

324
Q

Which has a better prognosis following excision +/- RT in dogs, oral SCC or FSA?

A

SCC
- MST not reached SCC, 557d (~19mo) FSA
- RT protective in incomplete margins for SCC (MST 2,000+d) vs 181d for FSA
- RT not protective for FSA

325
Q

Non-tonsilar oral SCC response to ECT?

A

27.3% - low toxicity

326
Q

RT for papillary SCC in dog

A
  • 10-16 daily x 3.2 Gy total >36
  • 9/10 CR - PFS/OST not reached
  • dog with PR PD at 228d
327
Q

Which mutation has been reported in up to 85% of k9 oral papillary SCC?

A

V595E

328
Q

What induced epithelial to mesenchymal transition in k9 oral SCC?

A

SLUG

329
Q

What is the effect of combining piroxicam and cisplatinum? Tumor types it may be effective against?

A
  • moderate to severe renal AE
  • OMM, SCC
330
Q

Marker of epithelial to mesenchymal transitions identified in feline SCC?

A

P-cadherin, Twist, HIF-a, and PDL1

  • Ncadherin which is classically associated with EMT not expressed
  • production of VEGF regulated by HIF-a was inhibited by dasatanib in vitro
331
Q

Protocol NOT recommended for cats with oral FSS d/t high morbidity and low RR?

A
  • bleomycin, piroxicam, thalidomide + RT (48Gy in 10 fx)
  • 30% grade III toxicity
332
Q

What mutation has been shown to be higher in feline oral SCC than inflammatory tissue?

A

p53

  • oral brushing may be an early detection method with 69% sensitivity and 97% specificity, accuracy 86% (pilot)
333
Q

Can mRNA detection of felus catus be used to dx oral SCC?

A

No- also elevate din ulcerative non cancer lesions with no sig difference between groups

334
Q

Fatty acid synthase expression has been shown in oSCC cell lines. What is an inhibitor?

A

Orlistat

335
Q

Which breeds are predisposed to peripheral odontogenic fibromas?

A

Boxer, Border terrier, Bassett hound
males

336
Q

In dogs with oral tumors who undergo full body staging (chest, abd) prior to surgery what is the frequency of IDing mets?

A
  • thx 4.9%, abd 2% (OMM in most)
  • incidental findings more common than mets.
  • thx 53%, and 81%, most common other tumors
337
Q

Is radical mandibulectomy a viable tx option for cats with oral tumors?

A

Yes
- MST 712 (~24mo) with 3 long term survivors dying of other causes
- 6/8 ate on their own

338
Q

What types of osteomas have been described in dogs? What do they look like?

A
  • peripheral and central
  • no evidence of bone lysis
339
Q

Most common salivary gland tumor?

A

adenocarcinoma

340
Q

DDX for tumor primary location in area of mandibular ramus on CT?

A

salivary, thyroid, ceruminous gland, laryngeal, tonsils

341
Q

What are prognostic factors for salivary carcinoma?

A

Stage; grade NOT prognostic

342
Q

MST dog salivary carcinoma treated with sialoadenectomy?

A
  • 1886d, 63 mo, 5 yr
  • local recurrence in 42%
  • DFI 299d
343
Q

Metastatic rate salivary carcinoma dog?

A

~30%

  • 29% of dogs may have local LN mets at time of surgery - removal encouraged but sstill associated with poor prognosis compared to no mets 98d vs 248d
344
Q

OST dogs with tonsillar carcinoma (various tx - Sx, RT, chemo, NSAIDs or comp)?

A
  • MST 126 d
  • PFI 91d
  • OST longer without overt mets
345
Q

Positive prognostic indicators associated with tonsil carcinoma?

A

absence of clinical signs, surgery, use of adjuvant chemo, and NSAIDs

346
Q

What percentage of malignant tonsil histo samples are metastatic?

A

~8% - some with unknown primary

-hematogenous route based on CT

347
Q

Survival range for cats with salivary carincoma treated with surgery (5) or RT (4)?

A

55-570d

348
Q

Most common laryngeal mass in cats?

A

LSA

349
Q

Can cats tolerate partial laryngectomy?

A

Yes - but often require temporary trach

350
Q

Which parasite is associated with esophageal tumors?

A

Spirocerca lupi
- OSA, fibrosarcoma, undiffentiated sarcoma
- can use fecal float to dx but not sens
- TX partial esophagectomy and dox MST 276d

351
Q

Esophageal tumor that may have a heredity component?

A

Leiomyomas

  • so not invade the mucosa but sarcomas will
352
Q

Most common esophageal tumor of cat?

A

SCC occurring in the middle 3rd of the esophagus

353
Q

Who is at higher risk for exocrine pancreas cancer?

A

older, female dogs, Spaniels

354
Q

Most common type of exocrine pancreatic cancner?

A

adenocarcinomas of ductular or acinar origin

-overall exceedingly rare <0.5% of all cancers

355
Q

What might be used on IHC to differentiate well differentiated and undifferentiated exocrine pancreatic carcinomas?

A

cluadin4

  • loss in undifferentiated
356
Q

General prognosis for exocrine pancreatic carcinoma?

A

Poor - often metastatic at time of dx to local LN

357
Q

What is a paraneoplastic syndrome for exocrine pancreatic cancer?

A

Alopecia on the ventrum of cats

358
Q

MST dogs diagnosed with exocrine pancreatic carcinoma?

A

-1 day, euth at dx
- 78% metastatic
- 1 dog diabetic

359
Q

Post surgical MST for cats with exocrine pancreatic carcinoma?

A

316d
- may be a viable tx for cats w/o mets

360
Q

Most common non-hematopeotic gastric cancer in dogs?

A

Gastric carcinoma

DDX: leiomyoma/sarcoma, GIST, MST. HS, plasmayctoma, undifferentiated sarcoma

361
Q

Most common gastric tumor in cats?

A

LSA > carcinoma

  • gastritic and H.pylori may be predisposing factor
362
Q

Metastatic rate gastric carcinoma in dogs?

A

32% at dx, 77% post mortem to LN > liver/lungs

363
Q

Dog presents with gastric tumor and hypoglycemia- what’s your top differential?

A

leiomyoma/sarcoma

  • excessive release of IGF-2
364
Q

IHC to differentiate GIST from leiomyosarcoma?

A

GIST express c-kit (CD117, exon 11) and CD34, vimentin+, DOG1+, weak SMA (smooth muscle actin)

leio express sma+, desmin+, kit-, dog1-

365
Q

Agreement between cytology and histo for gastric masses in cats and dogs?

A

poor ~50%

366
Q

ST following sx (Billroth, gastrectomy, gastronomy) for gastric carcinomas in dogs?

A
  • gaurded- 4-6 mo
  • persistent vomiting and anorexia common
  • 20% major complication rate (dehiscence)
  • adding chemo may improve survival (various: palladia, carbo, 5fu, etc)
367
Q

MST gastric tumors dogs

A

Carcinoma < 6 mo
GIST 37.4 mo
Leiomyosarcoma 8-12 mo
undifferentiated sarcoma 3 mo
MCT 1 mo
leiomyoma cured with surgery

368
Q

MST cats with gastric MCT?

A

~18 mo

369
Q

Cecal tumors are often?

A

GIST

25-32% may perf and cause acute abdomen

370
Q

Frequency of exon 11 mutations in GIST?

A

35%- conventional PCR
74%- RT-PCR
prior Q be careful

  • exon 9 5-10%
371
Q

Owner declines surgery for GIST - TX and MST?

A
  • Palladia
  • clear benefit in the gross disease setting
  • PFI 110d
  • less clear in microscopic disease setting (dogs with NED many months after stopping drug)
  • PFI 61d
  • Mets at dx and high MC associated with survival –> some are aggressive
372
Q

IHC prognostic for gastric carcinoma?

A
  • Vimentin expressed in 30%
  • higher in undifferentiated, emboli 82%, and mets 50%
  • associated with high Ki-67
  • high ki-67 associated with decreased ST
373
Q

Stem cell markers increased in intestinal adenomas/carcinomas compared to normal mucosa?

A

Sox9, DCLK1, survivin, Hopx

374
Q

MST SI adenocarcinoma tx with surgery?

A
  • 18 mo
  • 1 yr 60%, 2 yr 36%
  • chemo did not affect survival
  • dogs <8 yr did better
375
Q

Complication rate for submucosal resection via transanal approach for epithelial rectal tumors?

A
  • 29%
  • recurrence 215d (7mo)
376
Q

Categories of primary hepatic tumors ?

A
  • hepatocellular
  • bile duct
  • neuroendocrine (carcinoid)
  • mesenchymal

mets 2.5x more frequent than primary in liver

377
Q

HCC morphology and frequency? Met rate?

A

massive 50-80%, met 0-37%
nodular 16-25%
diffuse 19%
- both nodular and diffuse met 93-100%

  • most common liver tumor in dogs
  • > 2/3 left sided
378
Q

Most common hepatic tumor in cats?

A

HCC 42.5%, Bile duct carcinoma 32.5% (VCO 2022 paper)

Withrow says bile duct more common

379
Q

Metastatic rate bile duct carcinoma?

A

dog 88% LN, lungs
cat 67-80% carcinomatosis

380
Q

How do you differentiate neuroendocrine tumors from other hepatic tumors?

A

silver stain

381
Q

Behavior of non HCC hepatic tumors?

A

Most aggressive (sarcomas, neuroendocrine) met rates 80-100%

bile duct carcinoma MST < 6 mo after surgery

382
Q

True or false: degree of hepatocellular enzyme elevation can predict likelihood for cancer?

A

false

383
Q

Most common clin path abnormality in cats with liver tumors?

A

azotemia

  • also Tbili and ALT
384
Q

Paraneoplastic syndrome reported with hepatic adenoma?

A

hypoglycemia

385
Q

What may be helpful in differentiating HCC from other causes of liver disease?

A

hyperferritinemia

  • must r/o IMHA first (most common cause)
386
Q

Accuracy of FNA for HCC?

A

22.9% agreement to histo only 18.9% of cancer correctly diagnosed

387
Q

Most effective imaging technique to differentiate benign from malignant HCC?

A

3-phase CT; 2 phase not effective

388
Q

Which virus is associated with HCC in people?

A

hepatitis B AND woodchucks

389
Q

What factor is associated with better ST for sx for HCC?

A
  • completeness of excision
  • can be assessed intra op with flourescent imaging
390
Q

Intra op mortality rate HCC?

A

4.8%

  • 28.6% complication rate: hemorrhage, devascularization, transeint hypoglycemia and liver failure
  • transfusion needed in 17% of dogs and 44% of cats
391
Q

Local recurrence HCC dogs? Prognosis?

A

Complete margins
- 12% recurrence
- PFI 1000d (33 mo)
- MST 1836d (62 mo)

incomplete
- 58% recurrence
- PFI 521d (17 mo)
- MST 765 (25 mo)

  • nodular or diffuse = poor prognosis
392
Q

MST cats with HCC treated with liver lobectomy?

A

2.4 yr

393
Q

MST dogs HCC who do not undergo sx?

A

270 d (9 mo)

  • 15.4x more likely to die from their rutmor
394
Q

Prognostic factors HCC dogs?

A

surgical tx, side of tumor (R bad), high ALT, AST, ALT:AST ratio, margins

395
Q

RT for HCC?

A
  • must be 3D IMRT, in tradition liver cannot tolerate doses above 30 Gy
  • 18-42 Gy deliver 6-10 gY at a time
  • MST 567d (18mo); PRs mostly
  • SRT described in case report with on-going shrinkage at 10 mo
396
Q

Why is HCC chemo resistant?

A
  • role of hepatocytes in detoxification OR expression of P-gp
397
Q

Chemo with some reported responses for HCC?

A

Gemcitabine

  • MST massive 44 mo
  • nodule 32 mo
  • diffuse 3 mo
398
Q

Case report: dog with primary hepatic neuroendocrine carcinoma treated with dox/cytoxan, ST?

A

465 d, 15mo

399
Q

When might the ST for bile duct carcinoma be improved in dogs?

A

If localized and tx with liver lobectomy

  • MST 894d 30 mo
  • PFI 16 mo
400
Q

Response rate to Palladia for massive HCC?

A

50% (3/6 with PR and reduced liver enzymes)

  • increased VEGFR2 and ELE in non responders
401
Q

Alternative local tx for HCC?

A

chemoembolization

-with drug eluting bead CB 8, 2 dogs died from tx

  • w/o beads MST 419d 14 mo, hemmorhage and tumor volume poor prog
402
Q

Combined hepatocellular-cholangiocarcinoma dog outcomes?

A
  • massive tumors in all (14)
  • 14% intrahepatic mets at dx
  • MST 700d 23 mo post op
403
Q

Most common tumor type and prognosis for hemoabdomen secondary to liver tumor?

A
  • hCC 36% MST 897d 30 mo
  • benign 37% cured
  • HSA 45d
  • pre op ALT elevated + prog
  • anemia and transfusion -
404
Q

What can aid in detecting recurrence of HCC?

A
  • routine follow up with monitoring liver enzymes
  • no risk factors for recurrence in newer paper including margins
  • no difference in OST in those with occurrence than those without or if more tx is pursued
405
Q

Most common causes of non-islet cell hypoglycemia?

A

HCC, leiomyosarcoma
- IGF2 over expression

406
Q

Cat breed predisposed to intestinal tumors?

A

Siamese 1.8x more likely to get intesitnal cancer and 8x more likely for adenocarcinoma specifically

407
Q

Sites of intestinal tumor metastasis in decreasing frequency

A

LN (adenocarcinoma esp)> liver (leiomyosarcoma esp) > mesentery, spleen omentum, kidney, bone, peritoneum, lung

408
Q

Common sites of adenocarcinoma GI based on species?

A

Cat - SI
Dog - colorectal

409
Q

Breed predisposition inflammatory colorectal polyp?

A

doxin

410
Q

Paraneoplastic clinpath finding intestinal Tcell LSA?

A

hypereosinophilia secondary to IL5 secretion

411
Q

Perioperative mortality for intestinal tumors?

A

30-50% d/t sepsis

412
Q

1 year survival dogs with solid intestinal tumors?

A

40%

80% for GIST/leiomyosarcoma

413
Q

Chemotherapy shown to be effective for cats with colonic adenocarcinoma following subtotal colectomy?

A

Dox
MST 246d with 56d w/o

414
Q

Dog SI adenocarcinoma prognosis?

A
  • Guarded
  • ST 12 d no treatment
  • 4-10mo after sx
  • 5-FU used in ppl little info in dog
415
Q

Perianal gland tumor cytologic appearance?

A

hepatoid

416
Q

Perinal tumors in cats?

A

dont happen bc they dont have the same glands, AGASCA rare

417
Q

Signalment predisposition perianal adenomas?

A

intact male - growth stimulated by androgenic hormones and suppressed by estrogenic hormones

  • this is NOT true for adenocarcinomas which are rare but occur in castrated animals
418
Q

What might have led to perianal gland tumors formation in a female dog?

A
  • spay = lack of estrogen
  • can develop rarely secondary to Cushing’s
419
Q

Metastatic rate perianal adenocarcinoma at DX?

A

<15%
- occurs later to LN

420
Q

TX perianal adenoma? Carcinoma?

A
  • SX 1 cm margin only needed, castrate –> cure
  • ECT 90% ORR, 65% CR
  • SX 1+cm
  • can remove ~1/2 anal sphincter with minimal incontinence
421
Q

Prognosis perianal adenocarcinoma?

A
  • stage dependent
    -if <5cm T2 –> 2 yr control rate >60%
  • if mets 7 mo MST (ln excision may improve outcome
422
Q

Dog with hx of anal sac tumor removed, now hyperca with enlarged miln. Started ivf , next step?

A

FNA LN

423
Q

Histo findings in 95% of AGASACA?

A

solid and tables/rosette/pseudorossette patterns

424
Q

Frequency of hyperCA with AGASACA?

A

16-53%

425
Q

Metastatic rate AGASACA at time of dx?

A
  • overall 26-96%
  • 26-89% LN (can skip sacral to others in 75%)
  • 0-42% distant
  • tumor size not predictive but presence of CS may be
426
Q

E-cadherin is a cellular protein involved in adhesion and cell to cell communication. Loss of this protein is associated with decreased survival in which cancer?

A

AGASACA

427
Q

Prognosis non AGASACA anal sac tumors?

A

melanoma - poor, 50 MI/10hpf often metastatic

SCC- not metastatic often recurrence

428
Q

Complication rate after local AGASACA excision?

A

5-24% - dehiscence,, rectal perf, fistula, infection, transient incontinence

429
Q

Does lymphadenectomy improve survival for AGASACA?

A

Yes

  • 0-12% complication rate - hemorrhage, inability to resect
430
Q

Chemos with gross disease AGASACA response?

A

carbo
cisplatin
actinomycinD

post op use: mito, melphalan

  • NO SURVIVAL BENEFIT IN MULTIPLE STUDIES and even negative for DFI
431
Q

AGASACA Palladia response gross disease?

A
  • 69-88% CB
  • ~25% PR, 40-63% SD
  • duration 2.5-12 mo
  • resolution of hyperca reported
432
Q

AGASACA RT overall response gross disease?

A
  • 38% -75% hypofractionated or fractionated protocols
  • not shown to improve survival in microscopic disease
433
Q

AE AGASACA fractionated protocols

A
  • 15 x 3.2 Gy = 48 Gy
  • MST 956 days
  • 50% complications (late): rectal stricture, perf, chronic colitis
  • late AE more common if dose >3 / fx
  • acute AE: severe desquamination of perinal area and colitis lasting 1-4 weeks
  • image guided improves with 3.8 Gy x 12 showing no late and 73% acute grade I-II
434
Q

Clinical benefit rate hypofractionated RT AGASACA?

A
  • 63% including resolution of obstipation
  • 31% resolution of hyperCA with RT alone up to 77% when combined with pred and bisphosonate
  • PFI 10-11 mo
    -MST 8-15 mo
  • AE acute mild/infrequent, late rare
435
Q

Local recurrence rate AGASACA?

A

5-44% not dependent on completeness of margins

436
Q

DFI AGASACA tx with surgery +/- adjuvant chemo?

A
  • LN mets 134-197d, 4-7 mo
  • no mets 529-760d, 17-25 mo
  • When recurrence further surgery can improve ST, additional 12 mo reported with vs 47d w/o
437
Q

MST overall dogs AGASACA?

A

1-3 years

1 yr ST 65%
2 yr 29%

tumor related death range from 41-81%

438
Q

Favorable prognostic indicators AGASACA?

A

tumor < 2.5 cm, no mets

  • MST not reached only 9% died d/t tumor
439
Q

Negative prognostic indicators AGASACA?

A

size >2.5 cm, CS, LN mets, 4+ metastatic LN, distant mets, not doing sx, tx with chemo alone, e-cadherin loss, hyperCA

440
Q

Can sx still be considered for massive AGASACA (>5cm)?

A

Yes
- 18% intraop complication, 36% post op
- none permanent
- 37% local recurrence rate
- PFI 204d ~6mo
- OST 671d ~ 22 mo

441
Q

What % of post op analsacullectomy complications are high grade - requiring intervention?

A

68%
- infection and recurrence most common
- also intraop complication (anal rectal wall perforation) post op sig more likely

442
Q

RR and poor histo features cats with AGASACA?

A
  • 36% recurrent with median 96d
  • high nuclear pleomorphism
443
Q

Pituitary tumors most likely to excrete which hormone based on species?

A

dog: ACTH –> increased cortisol –> Cushings
cat: GH –> hyersomatotropism –> acromegaly

  • both adenoma, carcinomas rare
444
Q

MOA mitotane? Trilostane?

A

Mitotane - o,p’-DDD-lysodren, potent adrenocorticolytic that causes direct cytotoxicity to the adrenal

Trilostane - Vetoryl, synthetic corticosteroid analog that inhibits 3-B-hydroxysteroid dehydrogenase

445
Q

Blood test to dx acromegaly?

A

IGF1 - sens 84%, spec 92%

446
Q

MST SRT acromegaly cats?

A
  • 1,072d, 35 mo
  • 32% diabetic remission
  • 14% with previously elevated t4 became hypothyroid
447
Q

Does hormonal activity influence survival for pituitary dependent hyperadrenocrticism in dogs undergoing RT?

A
  • NO
  • DOse of RT does
  • fractioanted ST 605d (20 mo) vs 262d (8 mo) pRT
  • use fractionated
448
Q

What is recommended for SRT planning in pituitary macroadenomas?

A

CT + MRI
- single 17 Gy fx
- ~70% neuro improvement followed by decline 1.5-18 mo post SRT
- OST 1 year with 15% alive at 18 mo

449
Q

Dog MRI with pituitary mass (T1 hyper intense) what is the ST with definitive RT?

A

> 2 years

450
Q

Radiographic finding associated with adrenal tumor?

A

mineralization

451
Q
A

Onco boards 2024 (17 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions